The Quigley Corporation Introduces KIDZ-EEZE Lollipop to Soothe Sore Throats
Thursday April 10, 7:30 am ET
First Product in Quigley Line Targeted Specifically To Kids
DOYLESTOWN, Pa.--(BUSINESS WIRE)--April 10, 2003--The Quigley Corporation (Nasdaq:QGLY - News), marketer and distributor of COLD-EEZE®, the nation's leading pharmacist recommended over-the-counter zinc cold remedy, announced today the introduction of a sore throat lollipop under its all-new KIDZ-EEZE(TM) banner. Featuring pectin to soothe sore throats, the KIDZ-EEZE Sore Throat Pop will begin shipping to retail in August 2003. This introduction marks the first time that The Quigley Corporation has developed a product specifically addressing children's sore throats.
The KIDZ-EEZE Sore Throat Pop, containing 20 mg of pectin, is designed to soothe sore throats, one of the primary symptoms of the common cold. The pops, which also include 30 mg of Vitamin C and 4.4 mg of Zinc Gluconate, will be available in a random assortment of four great-tasting flavors: cherry, grape, orange and bubblegum.
"Combined with the recent announcement of our COLD-EEZE Zinc Gluconate Cold Remedy Nasal Spray, the debut of the KIDZ-EEZE Sore Throat Pop solidifies our position as a leader in the cold care category," said Guy J. Quigley, Chairman, President and Chief Executive Officer of The Quigley Corporation. "We are confident that this newest offering will appeal to parents and kids, while satisfying our retail customers with new, related Quigley products."
Packaging for the KIDZ-EEZE Sore Throat Pops will leverage the popularity of the COLD-EEZE brand while also clearly displaying the new KIDZ-EEZE logo. The launch of the pops will be supported with an integrated marketing campaign, including advertising, public relations and in-store support.
About The Quigley Corporation
The Quigley Corporation (Nasdaq:QGLY - News; www.quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar free tablets. COLD-EEZE is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Additional information about The Quigley Corporation is available on its Web site at www.quigleyco.com.
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations and worldwide competition.
--------------------------------------------------------------------------------
Contact:
G.S. Schwartz & Co., New York
Alissa Pinck (media), 212/725-4500
apinck@schwartz.com
or
The Investor Relations Group, New York
Lisa Lindberg (investors), 212/825-3210
theproteam@aol.com
--------------------------------------------------------------------------------
Source: The Quigley Corp. |
